Patents by Inventor Douglas J Dellinger

Douglas J Dellinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220275019
    Abstract: Compounds useful for forming nucleic acids having the structure of Formula I: Each of R1 or R2 is independently selected from hydrogen, a protecting group, or a phosphoramidite group. R3 is selected from H, F, O—C1-6 alkyl, O-MOE and a removable hydroxyl-protecting group. Q is a heterocyclic base. R4 is a cyclic hydrocarbon. Also disclosed are processes for forming the nucleic acids from the compounds and the nucleic acid products produced.
    Type: Application
    Filed: February 26, 2022
    Publication date: September 1, 2022
    Inventors: Benjamin D. Lunstad, Douglas J. Dellinger, Robert Kaiser
  • Publication number: 20220195425
    Abstract: Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.
    Type: Application
    Filed: March 14, 2022
    Publication date: June 23, 2022
    Applicants: The Board of Trustees of the Leland Stanford Junior University, Agilent Technologies, Inc.
    Inventors: Matthew H. Porteus, Ayal Hendel, Joe Clark, Rasmus O. Bak, Daniel E. Ryan, Douglas J. Dellinger, Robert Kaiser, Joel Myerson
  • Publication number: 20220195427
    Abstract: Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.
    Type: Application
    Filed: March 14, 2022
    Publication date: June 23, 2022
    Applicants: The Board of Trustees of the Leland Stanford Junior University, Agilent Technologies, Inc.
    Inventors: Matthew H. Porteus, Ayal Hendel, Joe Clark, Rasmus O. Bak, Daniel E. Ryan, Douglas J. Dellinger, Robert Kaiser, Joel Myerson
  • Publication number: 20220195426
    Abstract: Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.
    Type: Application
    Filed: March 14, 2022
    Publication date: June 23, 2022
    Applicants: The Board of Trustees of the Leland Stanford Junior Univerisity, Agilent Technologies, Inc.
    Inventors: Matthew H. Porteus, Ayal Hendel, Joe Clark, Rasmus O. Bak, Daniel E. Ryan, Douglas J. Dellinger, Robert Kaiser, Joel Myerson
  • Patent number: 11306309
    Abstract: Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: April 19, 2022
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Agilent Technologies
    Inventors: Matthew H. Porteus, Ayal Hendel, Joe Clark, Rasmus O. Bak, Daniel E. Ryan, Douglas J. Dellinger, Robert Kaiser, Joel Myerson
  • Patent number: 11299483
    Abstract: Compounds and methods for purifying oligonucleotides such as RNA and DNA. A target oligonucleotide is reacted with an orthoester linker comprising an affinity tag to form an orthoester oligonucleotide-orthoester linker conjugate which is subjected to a purification technique to separate the target oligonucleotide from impurities such as truncated oligonucleotides. The orthoester linker can be then removed under mild conditions to generate the target oligonucleotide in high purity.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: April 12, 2022
    Assignee: Agilent Technologies, Inc.
    Inventors: Douglas J. Dellinger, Joel Myerson, Brian Smart
  • Publication number: 20220002334
    Abstract: Aspects of the present disclosure include compositions that make use of phosphorus and/or nucleobase protecting groups which find use in the synthesis of long polynucleotides. Phosphorus protecting groups are provided that help increase the stepwise coupling yield and/or phosphorous protecting groups that can be removed during the oxidation step. Amidine nucleobase protecting groups are provided that find use in the subject compositions and methods which provides for e.g., increased resistance to depurination during polynucleotide synthesis. In some instances, the methods and compositions disclosed herein utilize a combination of the phosphorus and amidine nucleobase protecting groups in the synthesis of polynucleotides having a sequence of 200 or more monomeric units in length. Also provided are methods for synthesizing a polynucleotide (e.g., a DNA) using one or more compounds disclosed herein.
    Type: Application
    Filed: July 19, 2021
    Publication date: January 6, 2022
    Inventors: Douglas J. Dellinger, Luca Monfregola, Marvin Caruthers, Mithun Roy
  • Patent number: 11104699
    Abstract: Aspects of the present disclosure include compositions that make use of phosphorus and/or nucleobase protecting groups which find use in the synthesis of long polynucleotides. Phosphorus protecting groups are provided that help increase the stepwise coupling yield and/or phosphorous protecting groups that can be removed during the oxidation step. Amidine nucleobase protecting groups are provided that find use in the subject compositions and methods which provides for e.g., increased resistance to depurination during polynucleotide synthesis. In some instances, the methods and compositions disclosed herein utilize a combination of the phosphorus and amidine nucleobase protecting groups in the synthesis of polynucleotides having a sequence of 200 or more monomeric units in length. Also provided are methods for synthesizing a polynucleotide (e.g., a DNA) using one or more compounds disclosed herein.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: August 31, 2021
    Assignees: Agilent Technologies, Inc., University of Colorado Boulder
    Inventors: Douglas J. Dellinger, Luca Monfregola, Marvin Caruthers, Mithun Roy
  • Publication number: 20210079389
    Abstract: The present invention relates to modified guide RNAs and their use in clustered, regularly interspaced, short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems.
    Type: Application
    Filed: November 24, 2020
    Publication date: March 18, 2021
    Inventors: Daniel E. RYAN, Douglas J. DELLINGER, Jeffrey R. SAMPSON, Robert KAISER, Joel MYERSON
  • Patent number: 10900034
    Abstract: The present invention relates to modified guide RNAs and their use in clustered, regularly interspaced, short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: January 26, 2021
    Assignee: AGILENT TECHNOLOGIES, INC.
    Inventors: Daniel E. Ryan, Douglas J. Dellinger, Jeffrey R. Sampson, Robert Kaiser, Joel Myerson
  • Publication number: 20200339980
    Abstract: The present invention relates to guide RNAs having chemical modifications and their use in CRISPR-Cas systems. The chemically modified guide RNAs have enhanced specificity for target polynucleotide sequences. The present invention also relates to methods of using chemically modified guide RNAs for cleaving or nicking polynucleotides, and for high specificity genome editing.
    Type: Application
    Filed: July 15, 2020
    Publication date: October 29, 2020
    Inventors: Douglas J Dellinger, Daniel E Ryan, Subhadeep Roy, Jeffrey R Sampson
  • Patent number: 10767175
    Abstract: The present invention relates to guide RNAs having chemical modifications and their use in CRISPR-Cas systems. The chemically modified guide RNAs have enhanced specificity for target polynucleotide sequences. The present invention also relates to methods of using chemically modified guide RNAs for cleaving or nicking polynucleotides, and for high specificity genome editing.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: September 8, 2020
    Assignee: AGILENT TECHNOLOGIES, INC.
    Inventors: Douglas J Dellinger, Daniel E Ryan, Subhadeep Roy, Jeffrey R Sampson
  • Publication number: 20200190129
    Abstract: Compounds and methods for purifying oligonucleotides such as RNA and DNA. A target oligonucleotide is reacted with an orthoester linker comprising an affinity tag to form an orthoester oligonucleotide-orthoester linker conjugate which is subjected to a purification technique to separate the target oligonucleotide from impurities such as truncated oligonucleotides. The orthoester linker can be then removed under mild conditions to generate the target oligonucleotide in high purity.
    Type: Application
    Filed: August 17, 2018
    Publication date: June 18, 2020
    Inventors: Douglas J. DELLINGER, Joel MYERSON, Brian SMART
  • Publication number: 20200181124
    Abstract: Compounds and methods for purifying oligonucleotides such as RNA and DNA. A target oligonucleotide is reacted with an orthoester linker comprising an affinity tag to form an orthoester oligonucleotide-orthoester linker conjugate which is subjected to a purification technique to separate the target oligonucleotide from impurities such as truncated oligonucleotides. The orthoester linker can be then removed under mild conditions to generate the target oligonucleotide in high purity.
    Type: Application
    Filed: February 18, 2020
    Publication date: June 11, 2020
    Inventors: Douglas J. DELLINGER, Joel MYERSON, Brian SMART
  • Patent number: 10597421
    Abstract: A method of deprotecting a solid support bound polynucleotide comprising at least one 2?-protected ribonucleotide in which a step of contacting the polynucleotide with a composition comprising a diamine is performed under conditions sufficient to deprotect and cleave the polynucleotide which remains retained on the solid support.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: March 24, 2020
    Assignee: Agilent Technologies, Inc.
    Inventors: Douglas J. Dellinger, Joel Myerson, Agnieszka Sierzchala, Geraldine F. Dellinger, Zoltan Timar
  • Patent number: 10337001
    Abstract: The present invention relates to modified guide RNAs and their use in clustered, regularly interspaced, short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: July 2, 2019
    Assignee: AGILENT TECHNOLOGIES, INC.
    Inventors: Daniel E. Ryan, Douglas J. Dellinger, Jeffrey R. Sampson, Robert Kaiser, Joel Myerson
  • Publication number: 20190194242
    Abstract: Aspects of the present disclosure include compositions that make use of phosphorus and/or nucleobase protecting groups which find use in the synthesis of long polynucleotides. Phosphorus protecting groups are provided that help increase the stepwise coupling yield and/or phosphorous protecting groups that can be removed during the oxidation step. Amidine nucleobase protecting groups are provided that find use in the subject compositions and methods which provides for e.g., increased resistance to depurination during polynucleotide synthesis. In some instances, the methods and compositions disclosed herein utilize a combination of the phosphorus and amidine nucleobase protecting groups in the synthesis of polynucleotides having a sequence of 200 or more monomeric units in length. Also provided are methods for synthesizing a polynucleotide (e.g., a DNA) using one or more compounds disclosed herein.
    Type: Application
    Filed: October 29, 2018
    Publication date: June 27, 2019
    Inventors: Douglas J. Dellinger, Luca Monfregola, Marvin Caruthers, Mithun Roy
  • Patent number: 10196418
    Abstract: Aspects of the present disclosure include compositions that make use of phosphorus and/or nucleobase protecting groups which find use in the synthesis of long polynucleotides. Phosphorus protecting groups are provided that help increase the stepwise coupling yield and/or phosphorous protecting groups that can be removed during the oxidation step. Amidine nucleobase protecting groups are provided that find use in the subject compositions and methods which provides for e.g., increased resistance to depurination during polynucleotide synthesis. In some instances, the methods and compositions disclosed herein utilize a combination of the phosphorus and amidine nucleobase protecting groups in the synthesis of polynucleotides having a sequence of 200 or more monomeric units in length. Also provided are methods for synthesizing a polynucleotide (e.g., a DNA) using one or more compounds disclosed herein.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: February 5, 2019
    Assignee: Agilent Technologies, Inc.
    Inventors: Douglas J. Dellinger, Luca Monfregola, Marvin Caruthers, Mithun Roy
  • Publication number: 20180186826
    Abstract: A method of deprotecting a solid support bound polynucleotide comprising at least one 2?-protected ribonucleotide in which a step of contacting the polynucleotide with a composition comprising a diamine is performed under conditions sufficient to deprotect and cleave the polynucleotide which remains retained on the solid support.
    Type: Application
    Filed: December 12, 2017
    Publication date: July 5, 2018
    Inventors: Douglas J. Dellinger, Joel Myerson, Agnieszka Sierzchala, Geraldine F. Dellinger, Zoltan Timar
  • Publication number: 20180119140
    Abstract: Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.
    Type: Application
    Filed: October 3, 2017
    Publication date: May 3, 2018
    Applicants: The Board of Trustees of the Leland Stanford Junior University, Agilent Technologies, Inc.
    Inventors: Matthew H. Porteus, Ayal Hendel, Joe Clark, Rasmus O. Bak, Daniel E. Ryan, Douglas J. Dellinger, Robert Kaiser, Joel Myerson